Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results